Floatz logo

Carboplatin

Anal Canal Cloacogenic Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Anal Canal Cloacogenic Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
ECOG-ACRIN Cancer Research Group
Phase 2CCC
FLUOROURACILUM
ECOG-ACRIN Cancer Research Group
Phase 2CCC
FLUDEOXYGLUCOSE
ECOG-ACRIN Cancer Research Group
Phase 2CCC
Capecitabine
ECOG-ACRIN Cancer Research Group
Phase 2CCC
MITOMYCIN C
ECOG-ACRIN Cancer Research Group
Phase 2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →